4//SEC Filing
ABERCROMBIE GEORGE B 4
Accession 0001127602-21-025496
CIK 0000882796other
Filed
Sep 16, 8:00 PM ET
Accepted
Sep 17, 4:31 PM ET
Size
8.6 KB
Accession
0001127602-21-025496
Insider Transaction Report
Form 4
ABERCROMBIE GEORGE B
Director
Transactions
- Exercise/Conversion
Common Stock
2021-09-15$2.63/sh+5,000$13,150→ 5,000 total - Exercise/Conversion
Non-Qualified Stock Option
2021-09-15−5,000→ 0 totalExercise: $2.63Exp: 2021-10-10→ Common Stock (5,000 underlying) - Sale
Common Stock
2021-09-15$15.06/sh−5,000$75,300→ 0 total
Footnotes (3)
- [F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021.
- [F2]The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $14.90 to $15.40. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
- [F3]The option vested 1/8 per month for a period of 8 months, beginning on October 10, 2011.
Documents
Issuer
BIOCRYST PHARMACEUTICALS INC
CIK 0000882796
Entity typeother
Related Parties
1- filerCIK 0001485939
Filing Metadata
- Form type
- 4
- Filed
- Sep 16, 8:00 PM ET
- Accepted
- Sep 17, 4:31 PM ET
- Size
- 8.6 KB